Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Wednesday, June 09, 2021 at 11:30 a.m. IST to discuss the Audited Financial Results for the Q4 & FY21, to be declared on June 08, 2021. Suven Pharmaceuticals Ltd - 543064 - Board to consider FY 21 results & Final Dividend on June 08, 2021
Suven Pharmaceuticals Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on June 08, 2021, inter alia, to consider and approve the following matter(s):1. To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021.2. To consider and recommend a final dividend, if any, for the financial year ending March 31, 2021.Further note that TRADING WINDOW for dealing in the securities of the Company is already closed from April 01, 2021 as per PIT Code of the Company. Trading window will be opened from June 11, 2021. Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Tuesday, The 8Th June, 2021
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2021 ,inter alia, to consider and approve 1) To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021. 2) To consider and recommend a final dividend, if any, for the financial year ending March 31, 2021. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2021 as per PIT Code of the Company. Trading window will be opened from 11th June, 2021. Suven Pharmaceuticals Ltd - 543064 - Non-Applicability Of SEBI Circular - SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26, 2018 Issued In Respect Of 'Large Corporate'
With reference to the subject, we hereby confirm that for the financial year ended 31st March, 2021 our Company is not falling under the category of 'Large Corporate' as per the applicability criteria mentioned in SEBI Circular - SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. Please take this information on your record. Suven Pharmaceuticals Ltd - 543064 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 019181 Name of the Signatory :- K Hanumantha RaoDesignation :- Company Secretary and Compliance Officer Suven Pharmaceuticals Ltd - 543064 - Shareholding for the Period Ended March 31, 2021
Suven Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 40(10) For The Half-Year Ended 31St March, 2021
With reference to above subject, please find enclosed Compliance Certificate for the half-year ended 31st March, 2021 issued by the Practising Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record. Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Half-Year Ended 31St March, 2021
With reference to the above subject, please find enclosed compliance certificate for the half-year ended 31st March, 2021 duly signed by the Compliance Officer and authorised representative of the Share Transfer Agent (KFin Technologies Private Limited, Hyderabad), under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the Confirmation Certificate issued by KFin Technologies Private Limited, Registrar and Share Transfer Agents of the Company, for the quarter ended March 31, 2021.
CDMO leader ready to straddle entire pharma value chain
Except phosgenation and fluorination, Suven Pharma is capable of handling every other chemistry. This adds to the scope for contract engagements in speciality chemicals and clinical development for pharma